These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6984640)

  • 1. T-cell imbalance in progressive systemic sclerosis defined by monoclonal antibodies.
    Claudy AL; Le Petit JC; Barthelemy H; Garcier F
    Arch Dermatol Res; 1982; 274(1-2):189-92. PubMed ID: 6984640
    [No Abstract]   [Full Text] [Related]  

  • 2. T lymphocyte subpopulations in progressive systemic sclerosis defined by monoclonal antibodies.
    Czirják L; Surányi P; Dankó K; Szegedi G
    Acta Med Hung; 1985; 42(3-4):129-32. PubMed ID: 3879347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antilymphocyte antibodies in progressive systemic sclerosis.
    Labro MT; Perianin A; Kahn MF
    Clin Exp Rheumatol; 1983; 1(1):23-8. PubMed ID: 6398153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppressor cell function and T lymphocyte subpopulations in peripheral blood of patients with progressive systemic sclerosis.
    Whiteside TL; Kumagai Y; Roumm AD; Almendinger R; Rodnan GP
    Arthritis Rheum; 1983 Jul; 26(7):841-7. PubMed ID: 6223643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphocyte proliferative response to mitogenic monoclonal antibodies in systemic sclerosis. Evidence for unresponsiveness to murine monoclonal antibodies of IgG1 isotype.
    Valentini G; Carandente Giarrusso P; Gualdieri L; Corbo L; Alfinito F; Turco MC; Venuta S; Giordano M
    Tissue Antigens; 1989 Apr; 33(4):457-65. PubMed ID: 2734775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotype of peripheral blood lymphocytes in patients with progressive systemic sclerosis: activated T lymphocytes and the effect of D-penicillamine therapy.
    Freundlich B; Jimenez SA
    Clin Exp Immunol; 1987 Aug; 69(2):375-84. PubMed ID: 3498592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage infiltration in the skin of patients with systemic sclerosis.
    Ishikawa O; Ishikawa H
    J Rheumatol; 1992 Aug; 19(8):1202-6. PubMed ID: 1404154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoregulatory T cell subpopulations in patients with scleroderma using monoclonal antibodies.
    Keystone EC; Lau C; Gladman DD; Wilkinson S; Lee P; Shore A
    Clin Exp Immunol; 1982 May; 48(2):443-8. PubMed ID: 6213329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphocyte markers in patients with progressive systemic sclerosis.
    Czirják L; Dankó K; Sonkoly I; Bodolay E; Szegedi G
    Acta Med Hung; 1985; 42(3-4):109-14. PubMed ID: 2937012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of antithymocyte globulin in severe cases of progressive systemic sclerosis.
    Tarkowski A; Lindgren I
    Transplant Proc; 1994 Dec; 26(6):3197-9. PubMed ID: 7998113
    [No Abstract]   [Full Text] [Related]  

  • 11. Stimulation of lymphocyte reactivity by a low molecular weight cutaneous antigen in patients with progressive systemic sclerosis (scleroderma).
    Kondo H; Rabin BS; Rodnan GP
    J Rheumatol; 1979; 6(1):30-7. PubMed ID: 374734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological studies in childhood scleroderma.
    Stögmann W; Sandhofer M; Fritz J
    Eur J Pediatr; 1977 Feb; 124(3):223-30. PubMed ID: 300058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenesis of progressive systemic sclerosis.
    Postlethwaite AE; Kang AH
    J Lab Clin Med; 1984 Apr; 103(4):506-10. PubMed ID: 6607964
    [No Abstract]   [Full Text] [Related]  

  • 14. T-cell activation in the lungs of patients with systemic sclerosis and its relation with pulmonary fibrosis.
    Bresser P; Jansen HM; Weller FR; Lutter R; Out TA
    Chest; 2001 Jul; 120(1 Suppl):66S-68S. PubMed ID: 11451930
    [No Abstract]   [Full Text] [Related]  

  • 15. Abnormalities of immunoregulation in progressive systemic sclerosis. Evidence for excess helper-cell function and altered B-cell function.
    Krakauer RS; Sundeen J; Sauder DN; Scherbel A
    Arch Dermatol; 1981 Feb; 117(2):80-2. PubMed ID: 6451199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase in activated T cells and reduction in suppressor inducer T cells in systemic sclerosis.
    Gustafsson R; Tötterman TH; Klareskog L; Hällgren R
    Ann Rheum Dis; 1990 Jan; 49(1):40-5. PubMed ID: 2138008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunologic findings in progressive scleroderma--diagnostic and nosologic significance].
    Sönnichsen N; Brenke A; Barthelmes H; Albrecht-Nebe H; Diezel W
    Dermatol Monatsschr; 1983 Jun; 169(6):385-93. PubMed ID: 6603989
    [No Abstract]   [Full Text] [Related]  

  • 18. [Current findings in progressive systemic sclerosis].
    Zanussi C; Ortolani C; Pastorello E; Riboldi PS; Sabbadini MG
    Minerva Med; 1982 Apr; 73(18):1189-200. PubMed ID: 7043320
    [No Abstract]   [Full Text] [Related]  

  • 19. Polyclonal B lymphocyte activation in progressive systemic sclerosis.
    Famularo G; Giacomelli R; Alesse E; Cifone MG; Morrone S; Boirivant M; Danese C; Perego MA; Santoni A; Tonietti G
    J Clin Lab Immunol; 1989 Jun; 29(2):59-63. PubMed ID: 2632802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case history of a patient with multiple sclerosis and scleroderma.
    Jawad SH; Askari A; Ward AB
    Br J Rheumatol; 1997 Apr; 36(4):502-3. PubMed ID: 9159550
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.